Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA.

Press Release Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. admin October 26, 2023 View Press Release About Seraxis, Inc. Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes. Share .share-icon{fill:#0e202a;} share .face-icon{fill:#fff;} .tw-icon{fill:#fff;} .ln-icon{fill:#fff;} .pn-icon{fill:#fff;} Press Release Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy. admin November 12, 2018 Press Release Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia. admin July 16, 2023 Press Release Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD. admin September 28, 2023

The release as fetched from its publisher. seraxis.com ↗